Department of Oncology, Tongji Hospital of Tongji University, No. 389, Xincun Road, Putuo District, Shanghai 200065, China.
Department of Dermatology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Eur J Radiol. 2018 Mar;100:92-98. doi: 10.1016/j.ejrad.2018.01.009. Epub 2018 Jan 11.
To evaluate the efficacy and safety of radiofrequency ablation(RFA) for patients with lung cancers using meta-analysis.
A literature search (PubMed, Embase, Web of science and China National Knowledge Infrastructure) was undertaken until August 2017 to identify sufficient studies evaluating the efficacy and safety of RFA. Pooled proportions of estimates were calculated by performing the random effect model, including technical success rate, recurrence rate, local tumor progression rate and complications.
A total of 25 eligible studies were collected, giving a sample size of 1989 patients with 3025 lung tumors. In the present series, the pooled technical success rate was 96%(95%CIs: 93%-100%). Further, we observed pooled recurrence rate of 35%(95%CIs: 12%-59%) following RFA. Additionally, the pooled rate of local tumor progression was 26%(95%CIs: 20%-32%). One hundred and ninety major complications of RFA were reported in 20 studies, giving a pooled proportion of 6% (95%CIs: 3%-8%) for major RFA complications. Pooled rate of minor complications was 27% (95%CIs:14%-41%).
In this meta-analysis, RFA was found to be a safe and efficient treatment for the patients with lung cancers. The efficacy and safety of RFA for lung cancer deserve future investigation in further well-designed randomized controlled trials.
采用荟萃分析评估射频消融（RFA）治疗肺癌患者的疗效和安全性。
本研究检索了PubMed、Embase、Web of science 和中国知网（CNKI）中截至 2017 年 8 月的相关文献，以评估 RFA 治疗肺癌的疗效和安全性。采用随机效应模型计算汇总估计值，包括技术成功率、复发率、局部肿瘤进展率和并发症。
共纳入 25 项符合标准的研究，纳入的患者样本量为 1989 例，共 3025 个肿瘤病灶。汇总技术成功率为 96%（95%CI：93%-100%）。进一步观察发现 RFA 后复发率为 35%（95%CI：12%-59%）。此外，局部肿瘤进展率为 26%（95%CI：20%-32%）。20 项研究中报告了 190 例 RFA 主要并发症，主要并发症的汇总发生率为 6%（95%CI：3%-8%）。汇总的次要并发症发生率为 27%（95%CI：14%-41%）。
荟萃分析结果显示，RFA 治疗肺癌患者安全有效。RFA 治疗肺癌的疗效和安全性值得未来进一步开展设计良好的随机对照试验研究。
